Nkarta (NKTX) Common Equity (2019 - 2026)
Nkarta (NKTX) posted quarterly Common Equity of $285.9 million for Q1 2026, down 24.54% year-over-year from $378.8 million in Q1 2025, and down 8.47% quarter-over-quarter from $312.3 million in Q4 2025.
Nkarta (NKTX) Common Equity (2019 - 2026) Analysis & Trends
Nkarta's Common Equity history runs 8 years deep, the most recent figure standing at $285.9 million for Q1 2026.
- In Q1 2026, Common Equity fell 24.54% year-over-year to $285.9 million; the TTM figure through Mar 2026 stood at $285.9 million (down 24.54% YoY), while the FY2025 annual figure was $312.3 million, down 23.45% from the prior year.
- Common Equity for Q1 2026 stood at $285.9 million, down from $312.3 million in the prior quarter.
- The five-year high for Common Equity was $473.7 million in Q1 2024, with the low at $228.7 million in Q1 2022.
- The 5-year median for Common Equity is $357.7 million (2025), against an average of $358.5 million.
- Peak annual rise in Common Equity reached 51.57% in 2023, while the deepest fall reached 26.58% in 2023.
- Nkarta's Common Equity stood at $372.2 million in 2022, then dropped by 26.58% to $273.3 million in 2023, then jumped by 49.29% to $408.0 million in 2024, then dropped by 23.45% to $312.3 million in 2025, then slipped by 8.47% to $285.9 million in 2026.
- Business Quant data shows NKTX's Common Equity at $285.9 million in Q1 2026, $312.3 million in Q4 2025, and $337.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 9.79 Bn |
| 10 | Nkarta | 197.04 Mn | 197.04 Mn | - | 247.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 247.74 Mn |
| Mar 31, 2026 | 285.86 Mn |
| Dec 31, 2025 | 312.33 Mn |
| Sep 30, 2025 | 337.90 Mn |
| Jun 30, 2025 | 357.67 Mn |
| Mar 31, 2025 | 378.81 Mn |
| Dec 31, 2024 | 407.98 Mn |
| Sep 30, 2024 | 430.87 Mn |
| Jun 30, 2024 | 453.18 Mn |
| Mar 31, 2024 | 473.65 Mn |
| Dec 31, 2023 | 273.29 Mn |
| Sep 30, 2023 | 296.82 Mn |
| Jun 30, 2023 | 317.98 Mn |
| Mar 31, 2023 | 346.65 Mn |
| Dec 31, 2022 | 372.21 Mn |
| Sep 30, 2022 | 399.26 Mn |
| Jun 30, 2022 | 421.04 Mn |
| Mar 31, 2022 | 228.71 Mn |
| Dec 31, 2021 | 250.97 Mn |
| Sep 30, 2021 | 270.01 Mn |